Real-World Primary Resistance to First-Line Immune-Based
Combinations in Patients with Advanced Renal Cell Carcinoma
(ARON-1)

J 2024

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

SANTINI, Daniele, Haoran LI, Giandomenico ROVIELLO, Se Hoon PARK, Enrique GRANDE et. al.

Základní údaje

Originální název

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

Autoři

SANTINI, Daniele, Haoran LI, Giandomenico ROVIELLO, Se Hoon PARK, Enrique GRANDE, Jakub KUCHARZ, Umberto BASSO, Ondrej FIALA, Fernando Sabino Marques MONTEIRO, Alexandr POPRACH (203 Česká republika, domácí), Sebastiano BUTI, Javier MOLINA-CERRILLO, Martina CATALANO, Tomas BUCHLER, Emmanuel SERONT, Jawaher ANSARI, Zin W MYINT, Marwan GHOSN, Fabio CALABRO, Ray Manneh KOPP, Dipen BHUVA, Maria T BOURLON, Michela ROBERTO, Di Civita Mattia ALBERTO, Veronica MOLLICA, Andrea MARCHETTI, Andrey SOARES, Nicola BATTELLI, Marco RICCI, Ravindran KANESVARAN, Aristotelis BAMIAS, Camillo PORTA, Francesco MASSARI a Matteo SANTONI

Vydání

Targeted Oncology, Dordrecht, Springer, 2024, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.400 v roce 2023

Kód RIV

RIV/00216224:14110/24:00137425

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11523-024-01096-3

UT WoS

001314876900001

Klíčová slova anglicky

Advanced Renal Cell Carcinoma

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2025 14:46, Mgr. Tereza Miškechová

Anotace

V originále

Background Therapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients who have progressive disease as the best response, "primary refractory" (P-ref), face dismal outcomes. ObjectiveOur multicenter retrospective real-world study aims to assess the prevalence and clinicopathological characteristics of P-ref patients. Methods This study collected data from 72 centers across 22 countries (1709 patients), involving patients aged >= 18 years with metastatic clear cell renal cell carcinoma. All patients were treated with first-line immune-oncology combinations. Data included patient demographics, histology, metastatic sites, and treatment responses. Radiological assessments followed Response Evaluation Criteria in Solid Tumors version 1.1. Statistical analyses employed Kaplan-Meier method, Cox proportional hazard models, logistic regression, and the receiver operating characteristic curve. ResultsIn our study, the P-ref rate was 19%. Nivolumab/ipilimumab showed the highest P-ref rate (27%), while pembrolizumab/lenvatinib exhibited the lowest (10%). Primary refactory patients demonstrated significantly lower median overall survival (7.6 months) compared with non-Pref patients (55.7 months), p < 0.001. At the multivariate analysis, nephrectomy, sarcomatoid de-differentiation, intermediate/poor International Metastatic RCC Database Consortium risk, and bone and brain metastases emerged as significant predictors of overall survival for Pref patients with renal cell carcinoma. Logistic regression showed a significant relationship between liver metastases, intermediate/poor International Metastatic RCC Database Consortium risk, and no surgery and an increased risk of Pref. This study presents limitations, mainly because of its retrospective design. Conclusions The ARON-1 study provides valuable insights into P-ref patients, emphasizing the challenges of this precociously resistant subgroup. Identified predictors could guide risk stratification, aiding clinicians in tailored therapeutic approaches.

Citovat

SANTINI, Daniele, Haoran LI, Giandomenico ROVIELLO, Se Hoon PARK, Enrique GRANDE, Jakub KUCHARZ, Umberto BASSO, Ondrej FIALA, Fernando Sabino Marques MONTEIRO, Alexandr POPRACH, Sebastiano BUTI, Javier MOLINA-CERRILLO, Martina CATALANO, Tomas BUCHLER, Emmanuel SERONT, Jawaher ANSARI, Zin W MYINT, Marwan GHOSN, Fabio CALABRO, Ray Manneh KOPP, Dipen BHUVA, Maria T BOURLON, Michela ROBERTO, Di Civita Mattia ALBERTO, Veronica MOLLICA, Andrea MARCHETTI, Andrey SOARES, Nicola BATTELLI, Marco RICCI, Ravindran KANESVARAN, Aristotelis BAMIAS, Camillo PORTA, Francesco MASSARI a Matteo SANTONI. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). Targeted Oncology. Dordrecht: Springer, 2024, roč. 19, č. 6, s. 893-903. ISSN 1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-024-01096-3.

@article{2446225,
   author = {Santini, Daniele and Li, Haoran and Roviello, Giandomenico and Park, Se Hoon and Grande, Enrique and Kucharz, Jakub and Basso, Umberto and Fiala, Ondrej and Monteiro, Fernando Sabino Marques and Poprach, Alexandr and Buti, Sebastiano and MolinaandCerrillo, Javier and Catalano, Martina and Buchler, Tomas and Seront, Emmanuel and Ansari, Jawaher and Myint, Zin W and Ghosn, Marwan and Calabro, Fabio and Kopp, Ray Manneh and Bhuva, Dipen and Bourlon, Maria T and Roberto, Michela and Alberto, Di Civita Mattia and Mollica, Veronica and Marchetti, Andrea and Soares, Andrey and Battelli, Nicola and Ricci, Marco and Kanesvaran, Ravindran and Bamias, Aristotelis and Porta, Camillo and Massari, Francesco and Santoni, Matteo},
   article_location = {Dordrecht},
   article_number = {6},
   doi = {http://dx.doi.org/10.1007/s11523-024-01096-3},
   keywords = {Advanced Renal Cell Carcinoma},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)},
   url = {https://link.springer.com/article/10.1007/s11523-024-01096-3},
   volume = {19},
   year = {2024}
}

TY  - JOUR
ID  - 2446225
AU  - Santini, Daniele - Li, Haoran - Roviello, Giandomenico - Park, Se Hoon - Grande, Enrique - Kucharz, Jakub - Basso, Umberto - Fiala, Ondrej - Monteiro, Fernando Sabino Marques - Poprach, Alexandr - Buti, Sebastiano - Molina-Cerrillo, Javier - Catalano, Martina - Buchler, Tomas - Seront, Emmanuel - Ansari, Jawaher - Myint, Zin W - Ghosn, Marwan - Calabro, Fabio - Kopp, Ray Manneh - Bhuva, Dipen - Bourlon, Maria T - Roberto, Michela - Alberto, Di Civita Mattia - Mollica, Veronica - Marchetti, Andrea - Soares, Andrey - Battelli, Nicola - Ricci, Marco - Kanesvaran, Ravindran - Bamias, Aristotelis - Porta, Camillo - Massari, Francesco - Santoni, Matteo
PY  - 2024
TI  - Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
JF  - Targeted Oncology
VL  - 19
IS  - 6
SP  - 893-903
EP  - 893-903
PB  - Springer
SN  - 17762596
KW  - Advanced Renal Cell Carcinoma
UR  - https://link.springer.com/article/10.1007/s11523-024-01096-3
N2  - Background Therapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients who have progressive disease as the best response, "primary refractory" (P-ref), face dismal outcomes. ObjectiveOur multicenter retrospective real-world study aims to assess the prevalence and clinicopathological characteristics of P-ref patients. Methods This study collected data from 72 centers across 22 countries (1709 patients), involving patients aged >= 18 years with metastatic clear cell renal cell carcinoma. All patients were treated with first-line immune-oncology combinations. Data included patient demographics, histology, metastatic sites, and treatment responses. Radiological assessments followed Response Evaluation Criteria in Solid Tumors version 1.1. Statistical analyses employed Kaplan-Meier method, Cox proportional hazard models, logistic regression, and the receiver operating characteristic curve. ResultsIn our study, the P-ref rate was 19%. Nivolumab/ipilimumab showed the highest P-ref rate (27%), while pembrolizumab/lenvatinib exhibited the lowest (10%). Primary refactory patients demonstrated significantly lower median overall survival (7.6 months) compared with non-Pref patients (55.7 months), p < 0.001. At the multivariate analysis, nephrectomy, sarcomatoid de-differentiation, intermediate/poor International Metastatic RCC Database Consortium risk, and bone and brain metastases emerged as significant predictors of overall survival for Pref patients with renal cell carcinoma. Logistic regression showed a significant relationship between liver metastases, intermediate/poor International Metastatic RCC Database Consortium risk, and no surgery and an increased risk of Pref. This study presents limitations, mainly because of its retrospective design. Conclusions The ARON-1 study provides valuable insights into P-ref patients, emphasizing the challenges of this precociously resistant subgroup. Identified predictors could guide risk stratification, aiding clinicians in tailored therapeutic approaches.
ER  -

SANTINI, Daniele, Haoran LI, Giandomenico ROVIELLO, Se Hoon PARK, Enrique GRANDE, Jakub KUCHARZ, Umberto BASSO, Ondrej FIALA, Fernando Sabino Marques MONTEIRO, Alexandr POPRACH, Sebastiano BUTI, Javier MOLINA-CERRILLO, Martina CATALANO, Tomas BUCHLER, Emmanuel SERONT, Jawaher ANSARI, Zin W MYINT, Marwan GHOSN, Fabio CALABRO, Ray Manneh KOPP, Dipen BHUVA, Maria T BOURLON, Michela ROBERTO, Di Civita Mattia ALBERTO, Veronica MOLLICA, Andrea MARCHETTI, Andrey SOARES, Nicola BATTELLI, Marco RICCI, Ravindran KANESVARAN, Aristotelis BAMIAS, Camillo PORTA, Francesco MASSARI a Matteo SANTONI. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). \textit{Targeted Oncology}. Dordrecht: Springer, 2024, roč.~19, č.~6, s.~893-903. ISSN~1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-024-01096-3.

Přehled o publikaci